| Literature DB >> 31160909 |
Mahboube Ganji-Arjenaki1, Mahmoud Rafieian-Kopaei1.
Abstract
Inflammatory bowel disease (IBD) has been considered as a group of heterogeneous intestinal diseases that affects multiple organs outside of the gastrointestinal tract and is due to an uncontrolled inflammatory response mediated by the immune system. The IBD etiology has not been clearly defined, and it is considered as a multifactorial disease. Due to side effects of some conventional therapies, the consumption of complementary and alternative medicines, and in particular, the herbal therapy, more than before is increasing. Herbal therapy results for management of IBD by various mechanisms including leukotriene B4 inhibition, antioxidant activity, immune system regulation of nuclear factor-kappa B, as well as antiplatelet activity are favorable, and no unfortunate events have been yet reported. In this article, we aimed to review and report the herbal therapies established for management of human IBD or evaluated by animal IBD models. Their possible mechanisms of actions are also discussed.Entities:
Keywords: Herbal medicine; inflammatory bowel disease; medicinal plants; phytotherapy
Year: 2019 PMID: 31160909 PMCID: PMC6540767 DOI: 10.4103/jrms.JRMS_590_17
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Studies inspecting herbal medicines effects in animal models of colitis
| Plant | Part | Results | Model | Species | Study |
|---|---|---|---|---|---|
| Curcumin | ↓ loss of body weight↓Disease in histological colitis scores↓NF-κb↓decrease in activity index | DSS | Mouse | Deguchi | |
| Curcumin | ↓ iNOS and Colonic nitrites↓TNF-α ↓COX-2 | TNBS | Rat | Camacho-Barquero | |
| Glycoprotein | ↓NO, iNOS↓COX-2↓NF-κbp50 | DSS | Mouse | Oh and Lim[ | |
| Theaflavin-3,3×-digallate | ↓NF- κb↓IFN-gamma, TNF-α, and IL12, ↓iNOS | TNBS | Mouse | Ukil | |
| Polysaccharide | ↓WBC↓Ulcerative area and colon weight | TNBS | Rat | Liu | |
| Thearubigin | ↓Disruption of colonic architecture↓Infiltration of neutrophils↓Lipid peroxidation↓Diarrhea↓Activity of serine protease↓NO, iNOS↓NF- κb | TNBS | Mouse | Maity | |
| Tryptanthrin | ↓IL-2 and IFN gamma↓Colon damage | DSS | Mice | Micallef | |
| Zerumbone (asesquiterpenoid) | ↓ Colitis suppression↓IL-βb, TNF-α | DSS | Mouse | Murakami |
TNF=Tumor necrosis factor; NO=Nitric oxide; IL=Interleukin; NOS=Nitric oxide synthase; COX=Cyclooxygenase; NF=Nuclear factor; WBC=White blood cell; DSS=Dextran sulfate Sodium; TNBS=Trinitrobenzene sulfonic acid; NF-κB= Nuclear factor kappa-light-chain-enhancer of activated B cells; ↓=Decrease
Clinical trials on the effects of herbal treatments in patients having inflammatory bowel disease
| Plant name | Plant part | Study design | Number of patients | Duration of treatment | Results | Type of IBD | Study |
|---|---|---|---|---|---|---|---|
| Powder | Placebo-controlled, double-blind trial | 40 | 10 weeks | Complete remission in 65% of plants group in comparison to no remission in placebo group | CD | Micallef | |
| Gel | Placebo-controlled, double-blind trial | 44 | 4 weeks | Clinical remission in 9, improvement in 11, and good response in 14 patients on aloe group in comparison to 1, 1 and 2 patients in placebo group, respectively. Also significant improvement in histological scores and index of clinical colitis activity in aloe group | UC | Langmead | |
| Grass juice | Placebo-controlled, double-blind trial | 23 | 4 weeks | Significant improvement in severity of rectal bleeding and disease activity index. No serious side effects | UC | Ben-Arye | |
| Extract | Placebo-controlled, double-blind trial | 101 | 8 weeks | Significant reduction in the mean CRP level in 8th week in patients who received extract in comparison to placebo group | CD | Sandborn | |
| Seed | Open-label, parallel group, randomized | 105 | 12 months | Same as mesalamine in maintenance of remission | UC | Rodríguez-Cabezas | |
| Powder | Open-label, parallel group, randomized | 30 | 6 weeks | Improvement in more than one parameter such as stool properties in Boswellia group | UC | Gupta | |
| Oil | Placebo-controlled | 43 | 6 months | Stool consistency improved and also was maintained even when the treatment discontinued | UC | Greenfield | |
| Extract | Placebo-controlled, double-blind trial | 89 | 6 months | A marked decrease in endoscopic index and the index of disease-associated clinical activity | UC | Algieri |
CD=Crohn’s disease; UC=Ulcerative colitis; IBD=Inflammatory bowel disease